Loss of quiescence and impaired function of CD34+/cd38low cells one year following autologous stem cell transplantation

Haematologica

Volumn 98, Issue 12, 2013, Pages 1964-1971

  Woolthuis, Carolien M ^a   Brouwers Vos, Annet Z ^a   Huls, Gerwin ^a   de Wolf, Joost Th M ^a   Schuringa, Jan Jacob ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; EARLY GROWTH RESPONSE FACTOR 1; HEME OXYGENASE 1; PROTEIN FOS; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CD34 CELL; CD38 CELL; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PERIPHERAL BLOOD STEM CELL; SENSITIVITY ANALYSIS; STAINING; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD38; CELLS, CULTURED; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84889788497     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086744     Document Type: Article

References (30)

1. Lokhorst HM, van der HB, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113-20.
2. Vellenga E, van Putten WL, van't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111(2):537-43.
3. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, et al. Influence of preand post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-82.
4. Nademanee A. Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol. 2009;2(4):425-42.
5. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60.
6. Nieboer P, de Vries EG, Mulder NH, Sleijfer DT, Willemse PH, Hospers GA, et al. Longterm haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours. Bone Marrow Transplant. 2001;27(9):959-66.
7. Nieboer P, de Vries EG, Vellenga E, van Der Graaf WT, Mulder NH, Sluiter WJ, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1year analysis. Eur J Cancer. 2004;40(8): 1199-207.
8. Woolthuis C, Agool A, Olthof S, Slart RH, Huls G, Smid WM, et al. Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. Bone Marrow Transplant. 2011;46(1):110-5.
9. Thornley I, Sutherland DR, Nayar R, Sung L, Freedman MH, Messner HA. Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+. Blood. 2001;97 (6):1876-8.
10. Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol. 2005;23(27):6699-711.
11. Domenech J, Linassier C, Gihana E, Dayan A, Truglio D, Bout M, et al. Prolonged impairment of hematopoiesis after highdose therapy followed by autologous bone marrow transplantation. Blood. 1995;85 (11):3320-7.
12. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci. USA 2007;104(13):5431-6.
13. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell. 2011;9 (4):298-310.
14. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Levesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375-85.
15. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128(2):325-39.
16. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007;110 (8):3056-63.
17. Glimm H, Oh IH, Eaves CJ. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood. 2000;96(13):4185-93.
18. Gothot A, van der Loo JC, Clapp DW, Srour EF. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Blood. 1998;92(8):2641-9.
19. Szilvassy SJ, Meyerrose TE, Grimes B. Effects of cell cycle activation on the shortterm engraftment properties of ex vivo expanded murine hematopoietic cells. Blood. 2000;95(9):2829-37.
20. Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem. 1982;257(22):13704-12.
21. Yahata T, Takanashi T, Muguruma Y, Ibrahim AA, Matsuzawa H, Uno T, et al. Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood. 2011;118 (11):2941-50.
22. Wilson A, Laurenti E, Trumpp A. Balancing dormant and self-renewing hematopoietic stem cells. Curr Opin Genet Dev. 2009;19 (5):461-8.
23. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110 (2):719-26.
24. Min IM, Pietramaggiori G, Kim FS, Passegue E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the haematologica | 2013; 98(12) proliferation and localization of hematopoietic stem cells. Cell Stem Cell. 2008;2(4):380-91.
25. Cao YA, Wagers AJ, Karsunky H, Zhao H, Reeves R, Wong RJ, et al. Heme oxygenase-1 deficiency leads to disrupted response to acute stress in stem cells and progenitors. Blood. 2008;112(12):4494-502.
26. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95(11):3289-96.
27. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8(12):1313-23.
28. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C, et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature. 2009;459 (7245):387-92.
29. Khandanpour C, Sharif-Askari E, Vassen L, Gaudreau MC, Zhu J, Paul WE, et al. Evidence that growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. Blood. 2010;116(24):5149-61.
30. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell. 2011;20(5):591-605.